Xarelto Lawsuits Surpass 3000, Side Effects Include Death By Excessive Internal Bleeding

Xarelto, one of the present day drugs to help patients suffering from blood clotting, was approved for commercial launch in 2011. It’s manufactured by well-known pharmaceutics company, Bayer and marketed by Janssen Pharmaceuticals, a wholly-owned subsidiary of Johnson & Johnson (NYSE:JNJ). Everything was going well for Bayer and Xarelto until reports about Xarelto causing uncontrollable internal bleeding started pouring in.

Excessive Lawsuits About Xarelto

As of now, over 3,000 cases, including 2,400 lawsuits in Louisiana and 500 lawsuits in other parts of Philadelphia have been filed against Xarelto. The number is increasing day by day, and the plaintiffs don’t seem to stop accusing the manufacturers of this drug anytime soon.

Various reports claim that Xarelto doesn’t come with any antidote, which wasn’t revealed by Bayer previously. It means that if any patient suffers from excessive bleeding after taking Xarelto, he will have to wait until the drug gets out of his body naturally.

Just like its predecessor Coumadin, Xarelto was launched to reduce the risk of strokes and blood clots. However, the manufacturing company didn’t launch any antidote to control its anti-clotting properties, including the risk of excessive bleeding. It’s not that the patients taking anti-clotting drugs (Coumadin) didn’t face bleeding events in the past, but they always had an antidote in the form of vitamin K to control severe effects. With Xarelto, they don’t have any such option, which has caused this outrage.

What Drove People To File Lawsuits Against The Markers Of Xarelto

Plaintiffs from different parts of the world are filing lawsuits against Bayer, the manufacturer of Xarelto. Some of the major reasons that have prompted them to take this step are-

  • Financial challenges caused by ongoing care, emergency visits and lost wages
  • Emotional distress from seeing loved ones going through the pain
  • Holding manufacturers and marketers of this drug responsible for all the losses.

The response from Bayer and Janssen is still awaited. It will be great to witness how both these market leaders will get rid of this negative branding that has caused them millions of dollars and most importantly customers’ faith.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of argusjournal.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please click HERE

Leave a Reply

Your email address will not be published. Required fields are marked *